Showing 1561-1570 of 1697 results for "".
- Lifestyle Changes Improved Cognition, Function, Aβ Biomarkers in People with Early Alzheimer Disease According to RCThttps://practicalneurology.com/news/lifestyle-changes-improved-cognition-function-av-biomarkers-in-people-with-early-alzheimer-disease-according-to-rct/2470499/Lifestyle changes, including diet, exercise, stress management, and participation in support groups, were associated with improved cognition and function in people with mild cognitive impairment (MCI) or early dementia due to Alzheimer disease (AD). People who received usual care showed no improv
- 9 Leaders in Sleep Medicine & Research Honored at 2024 SLEEP Meetinghttps://practicalneurology.com/news/9-leaders-in-sleep-medicine-research-honored-at-2024-sleep-meeting/2470496/At the 2024 SLEEP meeting of the Associated Professional Sleep Societies in Houston, Texas, 9 awards were granted to leaders in sleep medicine and sleep research during the plenary session on Monday, June 3. These awards recognize individuals who have made singular contributions to the AASM
- Investigational Gene Therapy for Huntington Disease Receives RMAT Designation from FDA to Accelerate Developmenthttps://practicalneurology.com/news/investigational-gene-therapy-for-huntington-disease-receives-rmat-designation-from-fda-to-accelerate-development/2470495/AMT-130 (uniQure; Lexington, MA), an investigational gene therapy for the treatment of Huntington disease (HD), has been granted Regenerative Medication Advanced Therapy (RMAT) designation by the Food and Drug Administration (FDA). AMT-130 combines an adeno-associated virus (AAV) vector with a ge
- Dayvigo Improves Sleep Factors in Patients with COPDhttps://practicalneurology.com/news/dayvigo-improves-sleep-factors-in-patients-with-copd/2470493/Study results presented at the 2024 SLEEP meeting of the Associated Professional Sleep Societies demonstrated that Dayvigo (lemborexant; Easai, Woodcliff, NJ), a dual-orexin receptor antagonist Food and Drug Administration (FDA)-approved for the treatment of insomnia in adults, improved sleep ons
- Treatment of RLS with Horizant Reduces Nighttime Agitation & Improves Sleep in Patients with Dementiahttps://practicalneurology.com/news/treatment-of-rls-with-horizant-reduces-nighttime-agitation-improves-sleep-in-patients-with-dementia/2470492/Study results showed improved sleep and a reduction in nighttime agitation in dementia patients with restless legs syndrome (RLS) treated with Horizant (gabapentin enacarbil; Azurity Pharmaceuticals, Woburn, MA). These results were presented at the 2024 SLEEP meeting of the Associated Professiona
- Low-Sodium Narcolepsy Treatment Safe & Effective in Patients with Cardiovascular/Cardiometabolic Comorbiditieshttps://practicalneurology.com/news/low-sodium-narcolepsy-treatment-safe-effective-in-patients-with-cardiovascularcardiometabolic-comorbidities/2470490/Study results presented at the 2024 SLEEP meeting of the Associated Professional Sleep Societies demonstrated that Xywav (low-sodium oxybate; Jazz Pharmaceuticals, Dublin, Ireland) treatment for narcolepsy was safe and effective for those with cardiovascular (CV) and cardiometabolic (CM) comorbid
- Large Scale Survey of Patients with MS Uncovers Significant Barriers to Care: 42% of Respondents Do Not See an MS Specialisthttps://practicalneurology.com/news/large-scale-survey-of-ms-patient-needs-uncovers-significant-barriers-to-care-42-do-not-see-an-ms-specialist/2470481/Results from a large-scale, national survey highlight the significant barriers that people living with multiple sclerosis (MS) face in accessing resources and health care in the United States. The top barriers identified from the survey commissioned by The Multiple Sclerosis Association of Americ
- Otsuka Terminates Development of Potential Agitation Treatment for Alzheimer Diseasehttps://practicalneurology.com/news/otsuka-terminates-development-of-potential-agitation-treatment-for-alzheimer-disease/2470478/Otsuka Pharmaceutical (Tokyo, Japan) has terminated the development of AVP-786, a potential treatment for agitation associated with Alzheimer disease, after the drug failed to meet its primary endpoint in a phase 3 clinical trial (NCT03393520). The trial evaluated the efficacy of AVP-786 compared
- New Insights into ARIA-E Risk from Donanemab Studieshttps://practicalneurology.com/news/new-insights-into-aria-e-risk-from-donanemab-studies/2470464/In an effort to understand more about amyloid-related imaging abnormalities (ARIA) associated with anti-amyloid therapy, researchers analyzed pooled data from 3 studies involving donanemab (Eli Lilly and Company, Indianapolis, IN) therapy for individuals with early Alzheimer disease (AD):
- Long-Term Data Reveal CBD Treatment Linked to Significant Reductions in Focal-Onset Seizureshttps://practicalneurology.com/news/long-term-data-reveal-cbd-treatment-linked-to-significant-reductions-in-focal-onset-seizures/2470450/The use of cannabidiol (CBD) was associated with reductions in focal-onset seizure, including focal aware seizures (FAS), focal impaired awareness seizures (FIAS), and focal to bilateral tonic-clonic seizures (FBTCS), with an acceptable safety profile. These results of an analysis of a study popu